Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 source : Www.biospace.com save search
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 34.98%
H: 25.83%
C: 25.43%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.07%
H: 5.37%
C: 4.8%
vk2735 agonist therapeutics study phase 1
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
Published: 2023-03-23 (Crawled : 12:20) - biospace.com/
ENVB | $0.938 4.52% 4.33% 180K
|
Health Technology
|
| O: 2.56%
H: 0.04%
C: -5.0%
eb-373 study phase 1
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | News | $0.4634 -5.24% -5.52% 280K
|
Process Industries
|
| O: 0.65%
H: 3.21%
C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
ALPN | $64.57 0.03% 0.03% 1.2M
|
Health Technology
|
| O: 0.35%
H: 1.39%
C: -5.34%
alpn-303 sciences study phase 1
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Published: 2023-03-20 (Crawled : 23:00) - biospace.com/
FUSN | $21.4 -0.09% -0.09% 270K
|
Health Technology
|
| O: -2.17%
H: 3.69%
C: -1.48%
fpi-2059 tumors treatment pharmaceuticals therapy study phase 1
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
Published: 2023-03-20 (Crawled : 12:20) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: -3.55%
H: 2.21%
C: 1.47%
rg6501 opregen innovation therapy results phase 1
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
Published: 2023-03-16 (Crawled : 23:00) - biospace.com/
ALPN | $64.57 0.03% 0.03% 1.2M
|
Health Technology
|
| O: -1.37%
H: 5.93%
C: 5.04%
alpn-303 sciences meeting study phase 1
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.445 -1.22% -1.24% 230K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.46%
C: 7.46%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.55%
H: 1.07%
C: 0.77%
pyx-201 tumors trial phase 1
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
ABUS | $2.74 -0.36% -0.36% 340K
|
Health Technology
|
| O: -0.33%
H: 0.12%
C: -2.65%
ab-161 trial phase 1
Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
Published: 2023-03-15 (Crawled : 01:00) - biospace.com/
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -1.59%
H: 1.94%
C: 0.36%
gment-101 pharmaceuticals leukemia phase 1
Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-03-15 (Crawled : 15:20) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K
|
Transportation and Warehousing
|
| O: -3.85%
H: 8.0%
C: 1.2%
sbi-100 arm approval bioscience research study phase 1
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
prtx007 research meeting association therapeutics cancer study phase 1
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
MRSN | $2.89 -9.97% -11.07% 3.2M
|
Health Technology
|
| O: -12.12%
H: 13.3%
C: 12.81%
xmt-2056 trial therapeutics clinical hold phase 1
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
Published: 2023-03-08 (Crawled : 19:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K
|
Health Technology
|
| O: 2.12%
H: 2.52%
C: -5.6%
ph10 spray trial phase 1 major depressive disorder
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
Published: 2023-03-08 (Crawled : 14:00) - biospace.com/
QSAM | $8.14 -31.58% 3.2K
|
Manufacturing
|
| O: -6.18%
H: 5.68%
C: 5.68%
cyclosam fda clearance bone cancer study phase 1
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Published: 2023-03-08 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3252 15.67% 20K
|
Health Technology
|
| O: 1.27%
H: 4.0%
C: -2.5%
treatment trial diabetes phase 1
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-03-07 (Crawled : 15:00) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K
|
Transportation and Warehousing
|
| O: -9.67%
H: 10.33%
C: 7.01%
sbi-100 trial bioscience ophthalmic emulsion phase 1
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
DYAI 4 | $1.52 2.01% 1.97% 3.4K
|
Health Technology
|
| O: -0.71%
H: 21.43%
C: 20.71%
dyai-100 covid-19 candidate protein vaccine trial update phase 1
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.